Novo Nordisk’s new Wegovy pill hit the market this week. The Danish drug maker, best known for GLP-1 injections like Ozempic and Wegovy, is now the first company to manufacture and receive FDA approval for an oral GLP-1 pill for weight management.

The weight loss drug Wegovy is now available as a tablet in more than 70,000 U.S. pharmacies as well as select telehealth providers. The Food and Drug Administration recently approved an oral GLP-1 medication for the treatment of obesity and weight management.

The first GLP-1 oral pill is now available at pharmacies nationwide. The Wegovy pill was approved by the Food and Drug Administration on December 22.

And in a phase III trial win, Foresee Pharmaceuticals said its long-acting gonadotropin-releasing hormone agonist leuprolide mesylate -- already used to treat prostate cancer -- suppressed serum luteinizing hormone concentrations in children with central precocious puberty within 24 weeks.

The impact of popular U. S. weight-loss drugs like Ozempic and Wegovy (GLP-1 receptor agonists), upon their initial introduction to Americans, is showing many effects beyond just improving personal health.

On Monday, the Food and Drug Administration approved a pill version of Wegovy, Novo Nordisk’s wildly popular weight loss drug, officially launching the first oral GLP-1 medication ever cleared for obesity treatment.

A recent study revealed that GLP-1 drugs, Ozempic and Wegovy, primarily used for diabetes and weight loss, may assist in minimizing the risk of colon cancer.According to the research which is set to be presented at the American Society of

Ro Co-Founder and CEO Zach Reitano joins 'Fast Money' to talk the launch of Wegovy's oral GLP-1 offering, demand for the pill, and its partnership with Novo Nordisk to distribute the medication.